Surmodics (NASDAQ:SRDX) Research Coverage Started at StockNews.com

StockNews.com assumed coverage on shares of Surmodics (NASDAQ:SRDX) in a research report report published on Wednesday. The firm issued a hold rating on the stock.

A number of other research firms have also recently weighed in on SRDX. Sidoti reaffirmed a neutral rating and set a $43.00 price target on shares of Surmodics in a report on Wednesday, May 29th. Lake Street Capital reiterated a hold rating and set a $43.00 price target on shares of Surmodics in a research report on Wednesday, May 29th. Needham & Company LLC reissued a hold rating on shares of Surmodics in a research note on Monday, August 5th. Finally, Barrington Research restated a market perform rating on shares of Surmodics in a research note on Thursday, May 30th. Five analysts have rated the stock with a hold rating, Based on data from MarketBeat.com, the company currently has a consensus rating of Hold and an average target price of $50.00.

Surmodics Stock Down 0.4 %

SRDX stock opened at $38.83 on Wednesday. The stock has a market cap of $553.72 million, a PE ratio of 40.87 and a beta of 1.20. The firm’s 50-day simple moving average is $40.88 and its 200 day simple moving average is $35.70. Surmodics has a fifty-two week low of $25.17 and a fifty-two week high of $42.44. The company has a quick ratio of 3.22, a current ratio of 3.98 and a debt-to-equity ratio of 0.25.

Hedge Funds Weigh In On Surmodics

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. SG Americas Securities LLC lifted its holdings in shares of Surmodics by 14.7% in the first quarter. SG Americas Securities LLC now owns 5,138 shares of the company’s stock valued at $151,000 after buying an additional 660 shares during the period. Lazard Asset Management LLC lifted its holdings in Surmodics by 13.4% in the 1st quarter. Lazard Asset Management LLC now owns 5,679 shares of the company’s stock valued at $166,000 after acquiring an additional 673 shares during the last quarter. Hillsdale Investment Management Inc. boosted its position in shares of Surmodics by 15.7% during the 4th quarter. Hillsdale Investment Management Inc. now owns 4,570 shares of the company’s stock valued at $166,000 after purchasing an additional 620 shares in the last quarter. BNP Paribas Financial Markets grew its stake in shares of Surmodics by 7.5% in the 1st quarter. BNP Paribas Financial Markets now owns 6,878 shares of the company’s stock worth $202,000 after purchasing an additional 481 shares during the last quarter. Finally, Hardin Capital Partners LLC bought a new stake in shares of Surmodics in the 2nd quarter worth approximately $206,000. 96.63% of the stock is owned by institutional investors.

About Surmodics

Surmodics, Inc, together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD).